Aug 6 (Reuters) - Mylan NV reported a second-quarter profit on Thursday, helped in part by strong sales of its newly launched products such as asthma drug Wixela.
The drugmaker reported net earnings of $39.4 million, or 8 cents per share, in the three months ended June 30, compared to a loss of $168.5 million, or 33 cents per share, a year earlier.
Total revenue of the company, whose merger with Pfizer Inc’s off-patent branded drugs unit has been delayed by the pandemic, fell to $2.73 billion from $2.85 billion. (Reporting by Manojna Maddipatla and Trisha Roy in Bengaluru; Editing by Shounak Dasgupta)
Our Standards: The Thomson Reuters Trust Principles.